Daily Digest — October 10, 2026

Hit the market today

TRex Bio (TRXB)

TRXB · Priced 424B4 · $116.7 million raised · Nasdaq

TRex Bio priced at $14.00 per share — the bottom of its marketed range — raising net proceeds of $103.5 million from a biologics platform targeting atopic dermatitis and inflammatory bowel disease. Founded in 2018, the company has raised $220 million in equity financing to date and carries an accumulated deficit of roughly $123.6 million. Eli Lilly paid $55 million upfront for a collaboration, and that partnership anchors the scientific credibility — but the book priced at the floor, not the ceiling, which is the most candid signal the deal sent. Pro-forma cash and marketable securities of roughly $194.9 million fund operations through 2029; what happens between now and then pivots on a Phase 1b readout in atopic dermatitis expected mid-2027, with a U.S. patient population cited at 16 million. Full analysis: TRex Bio deep dossier.

---

Retension Pharmaceuticals (RTSN)

RTSN · Priced 424B4 · $45 million raised · terms set

Retension Pharmaceuticals priced at $12.00 per share, raising up to $45 million — or $45.1 million if the greenshoe exercises in full — against an implied market cap of roughly $100 million at the offer price. The company is a 2023 vintage small-molecule hypertension play with 12 employees, nine completed clinical trials, and 243 cumulative trial participants. Net proceeds of $38.9 million are guided to fund roughly 21 months of operations — the clock runs to approximately mid-2028, ahead of any Phase 2b efficacy readout. The safety dataset is real; the efficacy question remains unanswered at the time of pricing. Full analysis: Retension Pharmaceuticals deep dossier.

---

Just filed

Aspen Neuroscience

No ticker yet · Initial S-1 · terms not yet set

Aspen Neuroscience is developing an autologous iPSC-derived dopaminergic neuron therapy for Parkinson's disease — the proposition is that surgically implanted, patient-derived brain cells can functionally replace dead neurons, a question the FDA has never before been asked to evaluate at approval. Founded in 2018, the company has raised $347 million in private capital and holds both FDA Fast Track and RMAT designations. The ASPIRO trial has dosed 15 patients — 7 at low dose and 8 at high dose — with 12 reaching the six-month follow-up mark. Cash and marketable securities stand at roughly $72.4 million, against an accumulated deficit of roughly $264.9 million and a net loss of roughly $48.6 million in the most recent fiscal year. Phase 3 dosing is targeted for 2027, with long-term data readout penciled for 2028. The manufacturing process — autologous, built patient by patient — is the scientific differentiator and the operational constraint in the same breath. Terms not yet set.

---

Bambusa Therapeutics

No ticker yet · Initial S-1 · terms not yet set

Bambusa Therapeutics is a clinical-stage bispecific antibody company founded in 2024 with two candidates in clinical development, targeting atopic dermatitis and inflammatory disease. Its lead asset posted an EASI-50 response rate of 82% and EASI-75 of 64% at week 6 across 17 evaluable patients — signal that looks strong for a proof-of-concept and thin as a basis for a Phase 2b commitment. The company has raised $136.1 million in private financing, holds cash and marketable securities of $71.5 million, and posted a net loss of roughly $41.1 million in its most recent fiscal year. It has 30 employees, holds no issued patents, and the BioNTech Zhuhai license carries potential sales milestones of up to $217.5 million — contingent on a clinical program that hasn't yet begun Phase 2b. Terms not yet set.

---

Patriot Mobile

No ticker yet · Initial S-1 · terms not yet set

Patriot Mobile is a values-based wireless MVNO founded in 2013 with 186,000 active lines, an annual ARPU of $543, and average monthly churn of 1% — retention metrics that suggest real customer loyalty. The balance sheet is the harder story: $1 million in cash, a working capital deficit of $18.6 million, net losses of $3.3 million and $6.6 million in consecutive fiscal years, and a single underwriter. The filing carries going-concern language; convertible related-party notes are outstanding. The IPO is the bridge — the filing is, at this stage, the test of whether the loyalty thesis can fund a balance sheet repair. Terms not yet set.

---

Simwon America

No ticker yet · Initial S-1 · $18.00 to $22.00 per share indicated range

Simwon America manufactures structural body components — door rings and body-in-white assemblies — almost entirely for Tesla, which accounted for 99.49% of revenue in fiscal 2025 and 99.02% in fiscal 2026. Revenue has declined in each of the past two disclosed fiscal years: down 13.2% and then 9.7%. The company is profitable — net income of $16.9 million in the most recent fiscal year — but the IPO raises only $23.9 million in net proceeds for the company itself, while selling stockholders collect $18.6 million from secondary shares. Korean parent Simwon Tech retains 80.54% of the vote after the offering. New investors buying at the midpoint acquire shares with $8.31 in post-IPO net tangible book value — $11.69 per share of immediate dilution. The customer concentration is the whole risk; the secondary component and the governance structure are the context around it.